Work

A phase 2 study of glembatumumab vedotin (GV), an antibody-drug conjugate (ADC) targeting gpNMB, in advanced melanoma

Year: 2016

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdw379.42

Authors: P.A. Ott, A.C. Pavlick, D.B. Johnson, L.L. Hart, J.R. Infante, J.J. Luke, J. Lutzky, N. Rothschild, L. Spitler, C.L. Cowey, A. Alizadeh, A. Salama, Y. He, R.G. Bagley, J. Zhang, O. Hamid

Institutions: Dana-Farber Cancer Institute, NYU Langone Health, New York University, Vanderbilt University, Vanderbilt-Ingram Cancer Center, Tennessee Oncology, University of Chicago, Mount Sinai Medical Center, Florida Cancer Specialists & Research Institute, Northern California Melanoma Center, St. Mary's Medical Center, Baylor University Medical Center, Georgia Cancer Specialists, Duke University, Celldex Therapeutics (United States), Angeles Clinic and Research Institute

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funder: Merck

OpenAlex ID: W2586717419

FWCI: 0.773

Cites:

Cited by: 7

Related to: 10